Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

EMBL. (9/6/22). "Press Release: ERC Proof-of-Concept Grant Provides Way to Realise Commercial Potential of ‘SpaceM’ Technology".

Organisations Organisation SpaceM project (EMBL / BII Bio Studio Program)
  Organisation 2 EMBL (Heidelberg, main laboratory)
  Group EMBL (European Molecular Biology Laboratory)
Products Product mass spectrometry (MS)
  Product 2 metabolomics
Person Person Alexandrov, Theodore (EMBL 201410– Team Leader at EMBL Heidelberg before Univ Bremen)

Team Leader Theodore Alexandrov looks ahead with technology developed at EMBL that could aid drug discovery and development

[photo] Theodore Alexandrov and his team study cell-to-cell variation to pinpoint exactly when and how healthy cells become sick. This single-cell approach offers a way to develop better diagnostics and therapeutics and could be applied to many health conditions related to ageing, cancer, diabetes, and liver disease. Credit: Massimo del Prete/EMBL

A new Proof of Concept grant from the prestigious European Research Council will provide a way for fundamental metabolomics research to realise its commercial potential and promise in aiding drug development and precision medicine.

EMBL team leader Theodore Alexandrov will take forward an innovative technology developed through his earlier ERC Consolidator grant. Known as METADRUG, the new project aims to commercialize SpaceM, a method that Alexandrov and his research team developed to identify pivotal changes in a cell’s metabolites, which can help elucidate the mechanism of action of drugs, at the single-cell level.

“The technology of single-cell metabolomics can help address the crisis of modern drug development by offering novel capacities to profile metabolic drug response,” Alexandrov said. “What’s key, it can uniquely resolve differences between individual cells thus revealing information possibly critical, yet previously hidden, behind population averages.”

Studying cell-to-cell variation this way can also facilitate translational research by providing currently unavailable information on drug efficacy and safety. This can be used to develop better cancer diagnostics and therapeutics targeting rare tumour cells. It can also be applied to health conditions related to ageing, diabetes, and liver disease.

METADRUG will distinctly complement the commercialization of the SpaceM method already started at Denmark’s BioInnovation Institute (BII) under a recent collaboration agreement between EMBL and BII. SpaceM is the first project at BII under its new Bio Studio programme – a joint endeavour facilitated through EMBLEM, EMBL’s tech transfer arm.

Record changed: 2023-06-05


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for SpaceM project (EMBL / BII Bio Studio Program)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group World of Partnering Opportunities 650x300px

» top